Duarte, CANCT03460977Now EnrollingIRB Ready

Metastatic Castration Resistant Prostate Cancer (mCRPC) Clinical Trial in Duarte, CA

Access cutting-edge metastatic castration resistant prostate cancer (mcrpc) treatment through this clinical trial at a research site in Duarte. Study-provided care at no cost to qualified participants.

Sponsored by Pfizer

Quick Self-Assessment

See if you qualify for this Duarte location

Preparing your pre-screening questions…

Expert Care in Duarte

Access metastatic castration resistant prostate cancer (mcrpc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic castration resistant prostate cancer (mcrpc) treatment provided free

Apply for This Duarte Location

Check if you qualify for this metastatic castration resistant prostate cancer (mcrpc) clinical trial in Duarte, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Duarte

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Duarte site if eligible
  4. 4Begin participation

About This Metastatic Castration Resistant Prostate Cancer (mCRPC) Study in Duarte

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment. Part 3, which is open for enrollment is seeking men who: * have Castration Resistant Prostate Cancer (CRPC) and * have previously received treatment for CRPC and have progressed from the last treatment All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort). In the assessment phase: * participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods. * participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule. * participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule. After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding. The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.

Sponsor: Pfizer

Who Can Participate

Inclusion Criteria

Histological or cytological diagnosis of castration resistant prostate cancer.
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
Adequate bone marrow, renal, and liver function Part 3 Key

Exclusion Criteria

Prior irradiation to \>25% of the bone marrow.
QTcF interval \>480 msec at screening.
Hypertension that cannot be controlled by medications (\>150/90 mmHg despite optimal medical therapy).
Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
Prior enzalutamide within the last 4 weeks
DDI SUBSTUDY:
history of CHF or evidence of ventricular dysfunction
fructose intolerance
coadministration of CYP3A4 substrates

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Duarte?

Yes, this clinical trial (NCT03460977) has an active research site in Duarte, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Castration Resistant Prostate Cancer (mCRPC) Treatment Options in Duarte, CA

If you're searching for metastatic castration resistant prostate cancer (mcrpc) treatment options in Duarte, CA, this clinical trial (NCT03460977) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Duarte research site is actively enrolling participants for this clinical trial. You'll receive care from experienced metastatic castration resistant prostate cancer (mcrpc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic castration resistant prostate cancer (mcrpc) clinical trials near you to find additional studies recruiting in your area.

Ready to Join in Duarte?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Duarte, CA